Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches First Generic of Pred Forte in the US
Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Product Name : Pred Forte-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives USFDA Approval for Prednisolone Acetate Ophthalmic Suspension USP
Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Product Name : Pred Forte-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2024
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable